SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4606-4613. Prepublished online as a Blood First Edition Paper on September 14, 2007; DOI 10.1182/blood-2007-06-096966. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-06-096966v1 110/13/4606    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sorror, M. L. Articles by Storb, R. Search for Related Content PubMed PubMed Citation Articles by Sorror, M. L. Articles by Storb, R. Related Collections Transplantation Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Mohamed L. Sorror1, Sergio Giralt2, Brenda M. Sandmaier1,3, Marcos De Lima2, Munir Shahjahan2, David G. Maloney1,3, H. Joachim Deeg1,3, Frederick R. Appelbaum1,3, Barry Storer1,3, and Rainer Storb1,3 1 Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA; 2 M. D. Anderson Cancer Center (MDACC), Houston, TX; and 3 University of Washington, Seattle A new hematopoietic cell transplantation–specific comorbidity index (HCT-CI) was effective in predicting outcomes among patients with hematologic malignancies who underwent HCT at Fred Hutchinson Cancer Research Center (FHCRC). Here, we compared the performance of the HCT-CI to 2 other indices and then tested its capacity to predict outcomes among 2 cohorts of patients diagnosed with a single disease entity, acute myeloid leukemia in first complete remission, who underwent transplantation at either FHCRC or M. D. Anderson Cancer Center (MDACC). FHCRC patients less frequently had unfavorable cytogenetics (15% versus 36%) and HCT-CI scores of 3 or more (21% versus 58%) compared with MDACC patients. We found that the HCT-CI had higher sensitivity and outcome predictability compared with the other indices among both cohorts. HCT-CI scores of 0, 1 to 2, and 3 or more predicted comparable nonrelapse mortality (NRM) among FHCRC and MDACC patients. In multivariate models, HCT-CI scores were associated with the highest hazard ratios (HRS) for NRM and survival among each cohort. The 2-year survival rates among FHCRC and MDACC patients were 71% versus 56%, respectively. After adjustment for risk factors, including HCT-CI scores, no difference in survival was detected (HR: 0.98, P = .94). The HCT-CI is a sensitive and informative tool for comparing trial results at different institutions. Inclusion of comorbidity data in HCT trials provides valuable, independent information. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. R. Baer, H. D. Klepin, and A. S. Artz Acute Leukemia in Older Adults: Are We Treating Too Much or Too Little? ASCO Educational Book, January 1, 2008; 2008(1): 216 - 223. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020